Guillaume Lhermie is Associate Professor in Animal Health and Veterinary Public Health Economics at University of Toulouse, France, and Adjunct Assistant Professor at Cornell University, USA. Veterinarian by training, he also has an MSc in Economics and a PhD in pharmaco-epidemiology and innovation. Before working in academia, Dr. Lhermie worked in veterinary private practice for few years, as well as in the pharmaceutical industry, as R&D project manager and medical director over 8 years. Dr. Lhermie research interests are in One Health and Infectious Diseases challenges specifically the interface of animal agriculture and human health. He is studying the economics of antimicrobial use and resistance at the farm, supply chains, and global levels. Most recently, his research emphasis has been focusing on sustainability challenge, where he develops qualitative and quantitative models aiming to analyze the impact of antimicrobial use on social-ecological systems, to inform policymakers. Dr. Lhermie also serves as expert in animal health economics for governmental organizations and NGOs.
Preeti N. Malani, MD, MSJ is the University of Michigan’s Chief Health Officer and Professor of Medicine in the Division of Infectious Diseases. She is also the director of the University of Michigan’s National Poll on Healthy Aging. Her clinical expertise includes both infectious diseases and geriatric medicine. Dr. Malani is a graduate of the University of Michigan. She received her MD degree from Wayne State University School of Medicine. Prior to medical school, she completed a Master’s in Journalism at Northwestern University’s Medill School of Journalism. She completed her Internal Medicine residency and Infectious Diseases fellowship at the University of Michigan where she also received a Master’s Degree in Clinical Research Design and Statistical Analysis. Dr. Malani completed fellowship training in Geriatric Medicine at the Oregon Health and Science University. She has had a long standing interest in both the clinical and policy aspects of antimicrobial resistance, infection prevention, and infections in older adults. Dr. Malani has published more than 150 peer-reviewed articles and editorials and has edited five books. She continues to dabble in journalism and her recent work has appeared in a variety of publications including NPR, the Philadelphia Inquirer, Michigan Rivals, Health Affairs blog, and JAMA News. She serves on the public health committee of the Infectious Diseases Society of America.
Eleftherios E. Mylonakis
Dr. Eleftherios Mylonakis, Charles C.J. Carpenter Professor of Infectious Disease at Brown University, is also the Chief of Infectious Diseases at Rhode Island Hospital and the Miriam Hospital and Director of the COBRE Center for Antimicrobial Resistance and Therapeutic Discovery. He is Assistant Dean for Outpatient Investigations and Director of the Center for Outpatient and Longitudinal Medical Research at the Alpert Medical School of Brown University and Professor of Molecular Microbiology and Immunology. He was previously attending Physician of Infectious Disease at Massachusetts General Hospital and served as an Associate Professor at Harvard Medical School. Dr. Mylonakis studies host and microbial factors of infection and the discovery of antimicrobial agents. His research encompasses both clinical and laboratory studies and the use of mammalian and invertebrate model hosts systems to identify novel antimicrobial compounds and the elucidation of evolutionarily conserved aspects of microbial virulence and the host response. He has 8 patents, edited five books and published almost 400 articles in the peer-reviewed literature. He is currently named as a PI on a study of novel antimicrobials for Chemic Labs.
Iruka N Okeke is a Professor of Pharmaceutical Microbiology at the University of Ibadan, Nigeria and a Fellow of the Nigerian and African Academies of Science. Her research group investigates the mechanisms bacteria use to colonize humans, cause disease and gain drug resistance. She also studies laboratory practice in Africa. Iruka is a member of Nigeria’s Technical Working Group on Antimicrobial Resistance and her laboratory currently provides the genomic surveillance service for Nigeria’s antimicrobial resistance surveillance system as part of a collaborative UK National Institute for Health-supported Global Health Research Unit.
Iruka received B.Pharm., M.Sc. and Ph.D. degrees from Obafemi Awolowo University (formerly University of Ife), Nigeria and post-doctoral training at the University of Maryland, USA and Uppsala Universitet, Sweden. She has held Fulbright, International Federation for Science, Branco Weiss (Society-in-Science) and Institute for Advanced Studies (Berlin) fellowships as well as academic positions in Nigeria, the UK and the USA. Iruka is author/ co-author of several scientific articles and chapters as well as the books Divining Without Seeds: The case for strengthening laboratory medicine in Africa (Cornell Univ Press) and Genetics: Genes, Genomes and Evolution (Oxford Univ Press). She editor-in-chief of the African Journal of Laboratory Medicine. Iruka is on the Wellcome Trust’s Surveillance and Epidemiology of Drug Resistant Infections Consortium (SEDRIC) advisory board and currently serves as a volunteer drug resistance consultant to the Nigeria Centre for Disease Control (CDC), WHO and other organizations.
Emmanuel Okello is an Assistant Cooperative Extension Specialist in Antimicrobial Stewardship at University of California Davis. The goal of his extension program is to develop antimicrobial stewardship guidelines and best management practices that reduce the spread of antimicrobial resistance while maintaining the health and welfare of the herds and flocks. His research work is focused on understanding the dynamics and risks for antimicrobial resistance in livestock, and the development of health management strategies for reduced antimicrobial resistance and improved health and welfare of herds and flocks. Other areas of interest include the use of alternatives to antibiotics to control infectious diseases in livestock, and the development and evaluation of vaccines and rapid diagnostics tests. Prior to joining UC Davis faculty in 2018, Okello was a postdoctoral scholar at the UC Davis Veterinary Medicine Teaching and Research Center in Tulare, California. His postdoctoral research included surveillance for antimicrobial resistance on California dairies and developing decision tools to guide antimicrobial drug use for dairy cows. Okello earned his Bachelor of Veterinary Medicine from Makerere University in Uganda, Master of Molecular Biology from Katholieke Universiteit Leuven and a PhD in Bio-Engineering Sciences from Vrije Universiteit Brussel in Belgium.
Aylin Sertkaya, Ph.D. is a Vice President and Senior Economist at Eastern Research Group, Inc. (ERG) with over 20 years of experience in health economics, econometrics, health policy analysis, and program evaluation. Throughout her career at ERG, she has formed and led teams of economists, scientists, and nationally recognized subject-matter experts to support dozens of high-profile regulatory initiatives, working closely with federal agency economists and policymakers. Her applied research has been published in peer-reviewed journals, such as American Journal of Infection Control, Applied Health Economics and Health Policy, Clinical Trials, and Human and Ecological Risk Assessment. Dr. Sertkaya has led dozens of economic/policy analysis studies related to antibacterial products, diabetes intervention, unit dose medication barcoding, adoption of MedDRA for post-marketing periodic safety report submissions to FDA, drug compounding, among others under contract to the U.S. Food and Drug Administration and HHS Office of the Assistant Secretary for Planning and Evaluation. Her research on antibacterial products includes 1) the development of an analytical framework for evaluating the impact of different types of incentives on antibacterial product development, including drugs, vaccines, and rapid point-of-care diagnostic (see published reports Analytical Framework for Examining the Value of Antibacterial Products and Economic Incentives for the Development of Rapid Point-of-care (POC) Diagnostic Devices for C. Difficile, Carbapenem-resistant Enterobacteriaceae (CRE), and Neisseria Gonorrhoeae), 2) evaluation of the market performance of antibacterial drugs against their clinical value; examination of potential market failures that underlie lack of appropriate current or projected antibacterial therapies, and modeling the economic burden of antimicrobial resistance (ongoing project). Dr. Sertkaya holds a Ph.D. in Economics and a dual Bachelor’s in Physics and Economics.
Dr. Soupir an associate professor in the Agricultural and Biosystems Engineering Department; a member of the graduate faculty in the Civil, Construction, and Environ- mental Engineering Department; and Environmental Science and Sustainable Agriculture graduate degree programs at Iowa State University. Her research focuses on soil and water quality, nonpoint source pollution control, watershed management, and water quality monitoring. She uses both lab and field scale studies to examine the occurrence, fate and transport of pathogens, pathogen indicators and contaminants of emerging environmental concern (CoEECs) such as antibiotics and antibiotic-resistant bacteria to surface and tile drainage systems. Findings from her work have implications to improve the Total Maximum Daily Load (TMDL) development and implementation process, identify the impact of land use practices on water quality, and develop management practices to reduce pollutant transport. She works with landowners, commodity groups, and state and federal agencies to answer environmental questions and inform policy. Her goal is to protect public health and find ways to provide access to clean water for everyone.
Andy S. Stergachis
Andy Stergachis, PhD, MS, BPharm, is Professor of Pharmacy and Global Health and Adjunct Professor of Epidemiology and Health Services, Director of the Global Medicines Program, and Associate Dean for Research, Graduate Studies and New Initiatives, School of Pharmacy, University of Washington (UW). He is also Interim Director of the UW Biomedical Regulatory Affairs Program. Previously, he served as Chairman of the UW’s Department of Pharmacy and the Department of Pathobiology, and Associate Dean of the School of Public Health and founding Director of the UW Pharmaceutical Outcomes Research and Policy Program, now the CHOICE Institute. He is an author of 166 peer-reviewed publications in areas such as pharmacovigilance, pharmacoepidemiology, and clinical epidemiology. A licensed pharmacist, he served as Editor-in-Chief of the Journal of the American Pharmacists Association for 6 years until 2019. He was a member of the Drug Safety and Risk Management Advisory Committee, US FDA, and chaired the Expert Panel on the Review of Surveillance and Screening Technologies for the Quality Assurance of Medicines for USP through 2020. His current research in the field of antimicrobial resistance includes serving as co-investigator for a study to estimate the magnitude and trends in the global burden of antimicrobial resistance (AMR). Called the Global Research on Antimicrobial Resistance (GRAM) Project, he collaborates with the UW Institute for Health Metrics and Evaluation and the University of Oxford. He recently worked with the USAID-funded Medicines, Technologies, and Pharmaceutical Services (MTaPS) Program and MSH to conduct antimicrobial consumption and antimicrobial use projects in Tanzania. His completed research includes having directed a pharmacovigilance pregnancy registry study on the safety of first trimester antimalarials in sub-Saharan Africa countries. He is a pioneer in validation and use of large linked databases to evaluate the safety of medicines used in the US and, separately, in low- and middle-income countries. He has developed novel approaches for safety surveillance of drugs and vaccines and has contributed to strengthening the evidence-base for pharmacy services aimed at improving health and economic outcomes. Dr. Stergachis is an elected member of the National Academy of Medicine (NAM) and a Fellow of the American Pharmacists Association and of the International Society for Pharmacoepidemiology. He has served on multiple NAM committees, including the Committee on Evidence-Based Practices for Public Health Emergency Preparedness and Response; Committee to Review Long-Term Effects of Antimalarial Drugs; Committee on Strengthening Regulatory Systems in Developing Countries; and the Committee to Assess the U.S. Drug Safety System.
Mary E. Wilson
Mary E. Wilson, M.D. is Clinical Professor of Epidemiology and Biostatistics, University of California, San Francisco and Adjunct Professor of Global Health and Population, Harvard T.H. Chan School of Public Health. Her academic interests include antibiotic resistance, the ecology of infections and emergence of microbial threats, travel medicine, tuberculosis, and vaccines. She is a fellow in the Infectious Diseases Society of America, the American College of Physicians, the American Society of Tropical Medicine and Hygiene, and the International Society of Travel Medicine. She has served on the Advisory Committee on Immunization Practices (ACIP) of the CDC, the Academic Advisory Committee for the National Institute of Public Health in Mexico, and on five committees for the National Academies of Sciences, Engineering, and Medicine, where she was Vice-Chair of the Forum on Microbial Threats through 2019. She was a member of the Pew National Commission on Industrial Farm Animal Production, whose report, Putting Meat on the Table: Industrial Farm Animal Production in America, was released in the spring of 2008. She is the author of A World Guide to Infections: Diseases, Distribution, Diagnosis (Oxford University Press, 1991); senior editor, with Richard Levins and Andrew Spielman, of Disease in Evolution: Global Changes and Emergence of Infectious Diseases (NY Academy of Sciences, 1994); editor of New and Emerging Infectious Diseases (Medical Clinics of North America, 2008); author of Antibiotics: What Everyone Needs to Know (Oxford University Press, 2019); and is one of the medical editors for CDC’s Health Information for International Travel (Yellow Book). She has served as an advisor to the GeoSentinel Surveillance Network and is a contributing editor for NEJM Journal Watch Infectious Diseases. She served on the Board of Trustees for icddr,b in Bangladesh for 6 years, is a member of the Advisory Board for the Fogarty International Center at NIH, and on the Board of Directors for the Center for Disease Dynamics, Economics, and Policy.
Dr. Qijing Zhang is Clarence Hartley Covault Distinguished Professor and Associate Dean for Research and Graduate Studies in College of Veterinary Medicine at Iowa State University. Dr. Zhang received his PhD degree in immunobiology from Iowa State University and postdoctoral training in molecular microbiology from University of Missouri. Dr. Zhang worked as an Assistant Professor at the Ohio State University prior to returning to Iowa State University. For the past 20 years, Dr. Zhang’s research has focused on antimicrobial resistance (AMR) at the interface of human and animal medicine. His research has discovered emerging AMR threats, novel antibiotic resistance mechanisms, and co-evolution of bacterial virulence along with AMR in zoonotic and foodborne pathogens. His work has also provided key insights into the fitness, persistence, and transmission of AMR pathogens in the food chain, facilitating mitigation of AMR at the animal-human interface. In addition to AMR research, Dr. Zhang has broad perspectives on AMR surveillance, mitigation, and stewardship. Dr. Zhang is a fellow of American Academy of Microbiology and American Association for the Advancement of Science. He is also an honorary diplomate of American College of Veterinary Microbiologists.
Gillian Buckley - (Staff Officer)